Navigation Links
Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL)

llan University, Israel.

-- "Telaprevir (VX-950)-Resistant Variants Exhibit Reduced Replication Capacity Compared to Wild-Type HCV in Vivo and In Vitro," will be presented by Chao Lin of Vertex.

-- "Ultrasound Evaluation of Perihepatic Lymph Nodes During Antiviral Therapy with the Protease Inhibitor Telaprevir (VX-950) in Patients with Chronic Hepatitis C Infection," will be presented by Mireen Friedrich-Rust and Nicole Forestier, Saarland University Hospital, Germany.

-- "Neopterin and ALT as Markers of Inflammation in Chronic Hepatitis C Patients During Administration of the HCV NS3-4A Protease Inhibitor Telaprevir (VX-950) in Combination with PegInterferon Alpha 2A," will be presented by Huub Gelderblom, University of Amsterdam.

-- An oral presentation titled, "Molecular Basis for VX-950 Resistance," will be presented by Stefan Zeuzem, Saarland University Hospital, Germany, at 5:15 p.m. CEST (11:15 a.m. EDT) on Friday, April 13.

Two presentations discussing in vitro data of telaprevir in combination with other oral direct antiviral therapies will also take place during EASL.

Full abstracts are available on the EASL website: www.easl.ch/liver-meeting.

Webcast of Investor Presentation

Vertex intends to provide a live webcast of its investor presentation from Barcelona beginning at 7:30 p.m. CEST (1:30 p.m. EDT) on Saturday, April 14. The presentation may be accessed from the 'Events Calendar' on the homepage of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website until April 27, 2007. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Telaprevir (VX-950)

Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents in development that specifically targets HCV. V
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:4/21/2015)... , April 21, 2015 Cardiologists at Henry Ford ... stroke in patients with an irregular heartbeat. With ... Henry Ford is able to add another option ... fibrillation, which affects the heart,s ability to pump. ... and first-ever commercial Watchman implant at a non-clinical trial ...
(Date:4/21/2015)... -- According to a new market ... Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), ... Contamination, Adventitious Agents) - Global Forecast to 2019", ... Market was valued at $1,758.69 Million in 2014. ... CAGR of 12.23% to reach $3,130.85 Million in ...
(Date:4/21/2015)... -- Seattle Children,s announced today that 20 of 22 ... genetically reprogrammed T cells to treat relapsed acute lymphoblastic ... sensitive tests designed to detect minute amounts of cancer ... included children with very high tumor burdens as well ... "These results are extremely encouraging," said ...
Breaking Medicine Technology:Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 2Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 3
(Date:4/21/2015)... 2015 Carinsurancehints.com has released a new ... their impact on auto insurance prices . ... insurance prices. Clients should review their insurance options before ... bought under several forms. Some of the popular policies ... can compare online rates and find the best prices ...
(Date:4/21/2015)... On April 8th, 2015, Choices Recovery sponsored ... world famous Avalon Hollywood. Organized by Debbie Durkin, Los ... and film, the EcoLuxe Lounge is a premier red ... and festivals throughout the year. A gathering of some ... conscious products and services, this daylong event is attended ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing and ... the California Department of Food and Agriculture, have been ... Conference: The Future of Local Food, conference organizers announced ... known experts intensifies an already strong line-up of sustainable ... to speak at the June 11-13 event. ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 The ... Citrate Industry is a professional and in-depth study ... Sodium Citrate Market with a focus on ... in the sodium citrate market research are Cargill, ... Natural Biological, Cofco Biochemical, Capchem, Lianyungang Mupro Fi, ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Respected ... PACS® strategy , Visage Imaging Inc. (“Visage”), ... PME), has signed a seven-year contract with University ... in Northern Florida. The deal furthers the penetration ... hospital space, a key area of the North American ...
Breaking Medicine News(10 mins):Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4
... ... be a profitable 2010, the new Wella SP range is set to raise the ... ... hair company in the world, Wella is at the forefront of hairdressing innovation. The introduction ...
... ... struggle to find the balance between investing in the necessary internal resources to implement ... for a dozen online tactics, and identifies where companies are using each tactic in ... ...
... ... of the most common negative patterns in a relationship. Angry individuals may be aware of ... Path.com. , ... (PRWEB) February 1, 2010 -- Personal Power Path announces the launch of an anger management ...
... , Feb. 1 /PRNewswire / -- Ervin Cohen ... announced today that David Bricker , Of Counsel to ... clients last Friday, January 29, 2010 , in a medical malpractice ... Hopp of the Riverside Superior Court and a jury panel of 12. ...
... , BIRMINGHAM, Ala. , Feb. 1 ... Jon P. Stonehouse , President and Chief Executive Officer of BioCryst, plans ... forodesine and BCX4208 at the 12 th Annual BIO CEO ... at 10:30 a.m. Eastern Time . , Links to a ...
... contrast agent gadolinium during magnetic resonance imaging (MRI) for ... metastases, according to a new study published online February ... Institute . Gadolinium-enhanced MRI is primarily used to visualize ... and evaluate lymph node metastases. In light of this ...
Cached Medicine News:Health News:ckwrites.com Releases Report On Creating Online Marketing Tactics 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 3Health News:BioCryst To Present At 12th Annual BIO CEO & Investor Conference 2Health News:News brief: Contrast agent with MRI improves detection of lymph nodes metastases 2
The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 230 V, 50 Hz gel drying oven....
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
... Operating as a constant voltage power supply, the ... knob and hilo range switch control the output, ... to 250 volts. One, two-position switch toggles the ... output current. The 105 is equipped with an ...
... The 250-90 low voltage electrophoresis power supply ... 500 milliamps and 125 watts. This product operates ... continuously variable output. The 250-90 automatically crosses over ... when a preset limit is reached. ...
Medicine Products: